<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2025-197
Date of Submission: 2025-08-06

This report was submitted by a Pharmacist from Harris-Maynard Medical Center concerning patient ANON-PX-9923. The subject is a 61-year-old other with a significant medical history including seasonal allergies, atrial fibrillation, asthma. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities. 

Current medication review revealed the following suspected agent(s): Gabapentin administered via the Intravenous route at a dosage of 384mg, initiated on 2025-06-23 for Neuropathic pain and discontinued on 2025-07-12; Omeprazole (Proton-pump inhibitor) administered via the Subcutaneous route at a dosage of 271mg, initiated on 2025-06-23 for Gastroesophageal reflux disease and discontinued on 2025-07-12.

On approximately 2025-06-28, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Maculopapular Rash, Nausea, Stevens-Johnson syndrome. The Maculopapular Rash was classified as Mild in severity. This necessitated clinical intervention. The current patient status regarding this symptom is 'Recovered'. The Nausea was classified as Moderate in severity. This necessitated clinical intervention. The documented action was: Prescribed minute and advised might. The current patient status regarding this symptom is 'Unknown'. The Stevens-Johnson syndrome was classified as Mild in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Not Recovered'. 

CAUSALITY ASSESSMENT:
An evaluation of causality was performed. A Naranjo score of 6 was calculated, The assessment concluded the relationship was 'Probable'. Dechallenge/Rechallenge status was noted as: 'Positive dechallenge'. The on-site pharmacist concurred with the assessment during a routine case review. 

</data>
report_id: ADR-2025-197
report_date: '2025-08-06'
patient_details:
  patient_id: ANON-PX-9923
  gender: Other
  relevant_history:
  - seasonal allergies
  - atrial fibrillation
  - asthma
  age_at_reaction: 61
suspected_drugs:
- drug_name: Gabapentin
  dosage: 384mg
  route_of_administration: Intravenous
  start_date: '2025-06-23'
  indication_for_use: Neuropathic pain
  end_date: '2025-07-12'
- drug_name: Omeprazole
  dosage: 271mg
  route_of_administration: Subcutaneous
  start_date: '2025-06-23'
  indication_for_use: Gastroesophageal reflux disease
  drug_class: Proton-pump inhibitor
  end_date: '2025-07-12'
adverse_reactions:
- symptom_name: Maculopapular Rash
  onset_date: '2025-06-28'
  severity: Mild
  outcome: Recovered
  intervention_required: true
- symptom_name: Nausea
  onset_date: '2025-06-28'
  severity: Moderate
  outcome: Unknown
  intervention_required: true
  intervention_details: Prescribed minute and advised might.
- symptom_name: Stevens-Johnson syndrome
  onset_date: '2025-06-28'
  severity: Mild
  outcome: Not Recovered
  intervention_required: false
causality_assessment:
  assessment_conclusion: Probable
  dechallenge_rechallenge: Positive dechallenge
  naranjo_score: 6
reporting_facility: Harris-Maynard Medical Center
reporter_type: Pharmacist
